GenomeDx expands prostate cancer Dx reach with Medicare coverage deal

GenomeDx Biosciences CEO Doug Dolginow

GenomeDx Biosciences bagged Medicare coverage for its postoperative prostate cancer diagnostic, putting its test in the hands of more patients and helping the company gain ground in a crowded market.

The San Diego, CA-based company will work with Medicare national contractor Palmetto GBA to establish coverage for its Decipher genomic test for prostate cancer, a screening tool for men who have already had prostate cancer surgery but may be at risk for their cancer returning. The Medicare coverage policy covers men with prostate cancer who have positive surgical margins, pathological stage T3 disease or rising levels of prostate-specific antigen (PSA) after an initial test.

"This is an important milestone for GenomeDx and the thousands of men who may benefit from the valuable genomic information provided by Decipher," CEO Doug Dolginow said in a statement. "Our goal is to develop tests that will have a real benefit in terms of improved patient outcomes and savings to the healthcare system. The coverage of Decipher by Medicare is a huge step toward reaching that goal."

GenomeDx touts promising data for Decipher which show the test's improved accuracy in predicting aggressive prostate cancer. In published studies, 60% of men classified as high risk by traditional diagnostic tools were reclassified as low risk by the company's test, and 98.5% of the men did not have metastasis 5 years after surgery. Physicians also responded well to the results, opting to change their treatment recommendation 30 to 40% of the time based on results from Decipher, GenomeDx said in a statement.

The company has already made progress in gaining coverage for its prostate cancer test, inking deals in November 2013 with major PPOs including Three Rivers Provider Network and Fortified Provider Network to expand its test's reach. The insurers cover more than 62.6 million people combined.

But GenomeDx is not the only one developing innovative prostate cancer tests. The company faces competition from diagnostic outfits such as MDxHealth ($MDXH), VolitionRx and Genomic Health, which are forging ahead with R&D for their prostate cancer tools. In April, Belgium-based MDxHealth inked a deal with a Texas provider network to expand the reach of its signature ConfirmMDx prostate cancer test. In October, VolitionRX said it would team up with MD Anderson Cancer Center scientists to see whether a line of its assays could distinguish between two different forms of prostate cancer.

Meanwhile, Genomic Health continues to make headway on its prostate cancer tests, which predict the aggressiveness of the disease in men with low-risk. The Redwood City, CA-based company plans to expand into international markets and sees global revenue as a primary driver of growth, CEO Kim Popovits told FierceMedicalDevices last year.

- read the release

Special Reports: Five prostate cancer diagnostics to watch | Top women in medical devices 2014 - Kim Popovits, Genomic Health